Annual general meeting

CropLife Asia announces new Office Bearers for 2024

Retrieved on: 
Lunedì, Maggio 6, 2024
CropLife International, Annual general meeting, Science, Growth, Human, Farmer

SINGAPORE, May 6, 2024 - (ACN Newswire) - CropLife Asia, the regional voice of the plant science industry, today announced a new lineup for the organization's Office Bearers within the Board of Directors.

Key Points: 
  • SINGAPORE, May 6, 2024 - (ACN Newswire) - CropLife Asia, the regional voice of the plant science industry, today announced a new lineup for the organization's Office Bearers within the Board of Directors.
  • Following the CropLife Asia 2024 Annual General Meeting, changes include the installation of Mr. Rahoul Vijay Kumar Sawani as President of CropLife Asia with immediate effect.
  • The new roster for the CropLife Asia Office Bearers is as follows:
    "As climate change intensifies and farmers in Asia face increasing challenges with crop production, plant science plays an important role in ensuring a robust, resilient and sustainable food system for the region.
  • We're grateful to have experienced and strong leaders comprising our CropLife Asia Board of Directors at such a consequential time for our region," said Dr. Siang Hee Tan, Executive Director of CropLife Asia.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Recommend that SilverBow Resources Shareholders Vote “FOR” the Re-Election of SilverBow’s Three Director Nominees

Retrieved on: 
Giovedì, Maggio 9, 2024
Oil, Gas, Energy, Shirin David, Internet, ISS, Minyard, Annual general meeting, Institutional Shareholder Services, Eagle Ford, Dallas, Glass Lewis, Disclosure, Gold, Acquisition, Failure, Dissident, Glass, Telephone, ALL, Security (finance)

ISS and Glass Lewis recognize that SilverBow has the right Board and the right strategy to continue to deliver enhanced value for shareholders.

Key Points: 
  • ISS and Glass Lewis recognize that SilverBow has the right Board and the right strategy to continue to deliver enhanced value for shareholders.
  • The SilverBow Board remains committed to acting in the best interests of the Company and ALL SilverBow shareholders.
  • SilverBow strongly urges shareholders to follow ISS and Glass Lewis’s recommendations and vote “FOR” the re-election of SilverBow’s three highly qualified director nominees – Gabriel L. Ellisor, Kathleen McAllister and Charles W. Wampler – on the WHITE proxy card today.
  • If you have already voted using a gold proxy card, you may cancel that vote
    simply by voting again using the Company’s WHITE proxy card.

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Retrieved on: 
Giovedì, Maggio 9, 2024
Research, FDA, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, SGO, Society, Table, Cancer, Part, Fast track (FDA), Investment, Safety, NDA, Food, Abstract, New Drug Application, Gynecologic Oncology (journal), IND, ASCO, RAMP, Accelerated approval (FDA), Patient, Discovery, Research and development, FAK, Bank statement, BMS, Annual general meeting, Therapy, NSCLC, GAAP, Ovarian cancer, Verastem Oncology, Pharmaceutical industry

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the first quarter ended March 31, 2024.
  • Verastem Oncology ended the first quarter of 2024 with cash, cash equivalents and investments of $110.1 million.
  • Research & development expenses for the 2024 Quarter were $17.7 million, compared to $12.0 million for the 2023 Quarter.
  • Selling, general & administrative expenses for the 2024 Quarter were $10.4 million, compared to $7.3 million for the 2023 Quarter.

Rakuten Medical Announces Poster Presentation and Booth Exhibition at ASCO 2024 Annual Meeting

Retrieved on: 
Venerdì, Maggio 10, 2024
Safety, Poster, Carcinoma, Research, ASCO, Thomas Jefferson University, Society, Physician, Photoimmunotherapy, Convention, Otorhinolaryngology, Annual general meeting, SAN, Pharmaceutical industry

SAN DIEGO, May 9, 2024 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy based on its proprietary Alluminox™ platform, today announced that it will present a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO 2024), which will be held in Chicago, Illinois from May 31 through June 4, 2024.

Key Points: 
  • SAN DIEGO, May 9, 2024 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy based on its proprietary Alluminox™ platform, today announced that it will present a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO 2024), which will be held in Chicago, Illinois from May 31 through June 4, 2024.
  • Rakuten Medical will also have a booth in the Exhibit Hall.
  • The Company medical team will be pleased to welcome ASCO participants at booth #12118.
  • First Author: Takeshi Shinozaki, Department of Head and Neck Surgery, National Cancer Center Hospital East, Japan
    For more information and update, follow Rakuten Medical on LinkedIn or visit Rakuten Medical's booth at ASCO 2024.

Power Corporation Announces Election of Directors

Retrieved on: 
Giovedì, Maggio 9, 2024
Power Corporation of Canada, TSX, News, Annual general meeting

MONTRÉAL, May 9, 2024 /CNW/ - In accordance with the Toronto Stock Exchange Company Manual, Power Corporation of Canada (TSX: POW) (TSX: POW.PR.E) is issuing this news release to disclose that the nominees listed in its Management Proxy Circular dated March 20, 2024 were elected as its Directors.

Key Points: 
  • MONTRÉAL, May 9, 2024 /CNW/ - In accordance with the Toronto Stock Exchange Company Manual, Power Corporation of Canada (TSX: POW) (TSX: POW.PR.E) is issuing this news release to disclose that the nominees listed in its Management Proxy Circular dated March 20, 2024 were elected as its Directors.
  • The detailed results of the vote at its Annual Meeting of Shareholders held earlier today in Montréal, Quebec are set forth below.
  • On a vote by ballot, each of the following nominees proposed by management was elected as a Director:

Quebecor Inc. announces election of directors

Retrieved on: 
Giovedì, Maggio 9, 2024
TSX, Corporation, News, Proxy, Annual general meeting, Holding company

MONTRÉAL, May 9, 2024 /CNW/ - In accordance with the TSX Company Manual, Quebecor Inc. (TSX: QBR.A) (TSX: QBR.B) is issuing this news release to disclose the voting results for the election of directors held at its Annual Meeting of Shareholders held today.

Key Points: 
  • MONTRÉAL, May 9, 2024 /CNW/ - In accordance with the TSX Company Manual, Quebecor Inc. (TSX: QBR.A) (TSX: QBR.B) is issuing this news release to disclose the voting results for the election of directors held at its Annual Meeting of Shareholders held today.
  • All of the proposed nominees were duly elected as directors of the Corporation by the shareholders present or represented by proxy at the meeting.
  • The results of the vote were as follows:

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

Retrieved on: 
Giovedì, Maggio 9, 2024
Breast cancer, FDA, Cancer, SCCA, Paclitaxel, FOLFIRINOX, International, Pancreatic cancer, Research, Thought, Immunotherapy, Breast, TSX, PR, AB, Conference, ONC, ASCO, TIL, Anal canal, Patient, Society, Pancreatic Cancer Action Network, Anal, Ethics, Annual general meeting, Pelareorep, Type, Anal cancer, CGMP, Medical imaging

ET

Key Points: 
  • ET
    SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced recent operational highlights and financial results for the first quarter ended March 31, 2024.
  • General and administrative expenses for the first quarter of 2024 were $3.0 million, compared to $3.2 million for the first quarter of 2023.
  • Research and development expenses for the first quarter of 2024 were $5.7 million, compared to $3.5 million for the first quarter of 2023.
  • The net loss for the first quarter of 2024 was $6.9 million, compared to a net loss of $6.4 million for the first quarter of 2023.

Canadian Tire Corporation Announces Election of Directors

Retrieved on: 
Giovedì, Maggio 9, 2024
Meeting, TSX, CTC, Indian stock exchange, Annual general meeting

TORONTO, May 9, 2024 /CNW/ - Canadian Tire Corporation, Limited (the "Company") (TSX: CTC) (TSX: CTC.A) announced that at its Annual Meeting of Shareholders (the "Meeting") held today, the sixteen director nominees set out in the Company's Management Information Circular dated March 7, 2024 were elected as directors of the Company.

Key Points: 
  • TORONTO, May 9, 2024 /CNW/ - Canadian Tire Corporation, Limited (the "Company") (TSX: CTC) (TSX: CTC.A) announced that at its Annual Meeting of Shareholders (the "Meeting") held today, the sixteen director nominees set out in the Company's Management Information Circular dated March 7, 2024 were elected as directors of the Company.
  • On a vote by a show of hands, the following 13 individuals proposed by the Board of Directors as nominees were elected as directors of the Company by the holders of Common Shares.
  • The Company received the following proxy votes in advance of the Meeting from the holders of Common Shares with respect to the election of the 13 director nominees:

Norfolk Southern announces shareholders have elected 10 of 13 of the company's director nominees

Retrieved on: 
Giovedì, Maggio 9, 2024
Annual general meeting, NSC, Security (finance), United States Navy, Ernst & Young, Gas, Mitch Daniels, Management

ATLANTA, May 9, 2024 /PRNewswire/ -- Norfolk Southern Corporation (NYSE: NSC) announced today that the preliminary vote count of its proxy solicitor indicates that its shareholders have voted to elect 10 of Norfolk Southern's director nominees at the 2024 Annual Meeting of Shareholders, including:

Key Points: 
  • Norfolk Southern issued the following statement:
    We appreciate the support of our shareholders and the valuable perspectives they have shared with us in the months leading up to our Annual Meeting.
  • Our shareholders recognize that positive change is underway at Norfolk Southern.
  • We will work constructively and collaboratively on behalf of our shareholders unlocking the full potential of our powerful franchise.
  • Final results will be reported on a Form 8-K that will be filed with the Securities and Exchange Commission.

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting

Retrieved on: 
Giovedì, Maggio 9, 2024
Cancer, Blood, Tissue, Poster, MD, Cell, Hereditary angioedema, KLKB1, Patient, Gene, Society, HAE, Annual general meeting, Therapy, DSM-IV codes, SAN, Vaccine

SAN DIEGO, May 9, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today highlights new preclinical data supporting the potential of its fully non-viral lead genetic medicines programs and related platform technologies. The data was included in three oral and three poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting, being held in Baltimore, MD and virtually on May 7-11, 2024.

Key Points: 
  • The data was included in three oral and three poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting, being held in Baltimore, MD and virtually on May 7-11, 2024.
  • HAE patients have significant unmet need for a durable, effective, and convenient treatment option that eliminates recurrent attacks.
  • P-KLKB1-101 is a fully non-viral investigational gene editing therapy designed to enable high fidelity editing at pre-kallikrein, or KLKB1, for targeted correction of HAE.
  • Poseida also identified a class of amphipathic small molecules called Poseida Delivery Excipients (PDEs) with unique capabilities for enhancing DNA delivery.